PARKINSON DISEASE study: VIM0423
Official title A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
ClinicalTrials.gov ID: NCT07804615
What this study is testing
What is VIM0423?
VIM0423 is an investigational combination drug being studied for Parkinson’s disease tremor.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if VIM0423 can reduce tremor, is safe and well tolerated, and whether it helps people’s daily life and quality of life.
- Who it's for
- Adults with Parkinson’s disease whose tremor is not well controlled by standard dopaminergic medicines.
- What's involved
- Participants will receive either VIM0423 or a placebo, have regular clinic visits, and undergo tests to measure tremor, safety, and daily functioning.
- Time commitment
- The trial lasts several months, with multiple scheduled visits for medication administration and assessments.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening).
- Diagnosis of clinically probable or clinically established idiopathic Parkinson's disease (PD) at Visit 1 (Screening) established by the MDS 2015...
- Cohort 1: Currently using levodopa (any oral form only) or oral dopamine agonist at a stable dose and regimen of at least 10 weeks prior to Visit 1...
- The participants must meet protocol-specified requirements for baseline tremor scores.
You likely can't join if
- Currently (within 7 days of Screening) taking any anticholinergic medication.
- Prior deep brain stimulation (DBS) or any other form of invasive neurosurgical intervention (including, but not limited to, magnetic resonance-guided...
The study team makes the final eligibility decision.
Where it is enrolling
- Murrieta, California, United States
- Decatur, Georgia, United States
- Farmington Hills, Michigan, United States
- Memphis, Tennessee, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Murrieta, California, United States; Decatur, Georgia, United States; Farmington Hills, Michigan, United States; Memphis, Tennessee, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.